STAAR Surgical (NASDAQ:STAA) shares traded down 8% on Monday . The company traded as low as $24.20 and last traded at $24.42. 524,560 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 449,044 shares. The stock had previously closed at $26.55.

A number of research analysts recently weighed in on the company. Zacks Investment Research cut STAAR Surgical from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. ValuEngine cut STAAR Surgical from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. BidaskClub cut STAAR Surgical from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $38.00 target price (down previously from $43.00) on shares of STAAR Surgical in a report on Monday, May 6th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $40.33.

The company has a market capitalization of $1.11 billion, a P/E ratio of 89.21 and a beta of 2.02. The company has a quick ratio of 4.83, a current ratio of 5.41 and a debt-to-equity ratio of 0.04.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.06. The company had revenue of $32.58 million for the quarter, compared to analysts’ expectations of $32.40 million. STAAR Surgical had a return on equity of 13.22% and a net margin of 4.44%. During the same quarter in the previous year, the firm posted $0.01 earnings per share. On average, research analysts forecast that STAAR Surgical will post 0.3 earnings per share for the current fiscal year.

In other STAAR Surgical news, CEO Caren L. Mason sold 7,500 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $36.25, for a total transaction of $271,875.00. Following the transaction, the chief executive officer now owns 44,013 shares in the company, valued at $1,595,471.25. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction on Friday, May 3rd. The shares were bought at an average price of $22.23 per share, for a total transaction of $2,223,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 17,730 shares of company stock worth $655,538. 3.90% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of STAA. AdvisorNet Financial Inc lifted its stake in shares of STAAR Surgical by 600.0% during the fourth quarter. AdvisorNet Financial Inc now owns 875 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 750 shares in the last quarter. Mascoma Wealth Management LLC acquired a new position in shares of STAAR Surgical during the first quarter worth about $38,000. Macquarie Group Ltd. lifted its stake in shares of STAAR Surgical by 228.6% during the first quarter. Macquarie Group Ltd. now owns 1,354 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 942 shares in the last quarter. Aspire Private Capital LLC acquired a new position in shares of STAAR Surgical during the first quarter worth about $51,000. Finally, First Quadrant L P CA acquired a new position in shares of STAAR Surgical during the fourth quarter worth about $92,000. Institutional investors own 90.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2019/05/15/staar-surgical-staa-shares-down-8.html.

About STAAR Surgical (NASDAQ:STAA)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Article: What is the Fibonacci sequence?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.